Back

Antiarrhythmic drugs in blanking period after catheter ablation of atrial fibrillation do not change effectiveness of the procedure but add clinical benefit

21 June 2017 (09:30 - 09:40)
Organised by:
Congress Presentation Part of: Rapid Fire session 8 - Atrial fibrillation and stroke prevention Antiarrhythmic drugs (Atrial Fibrillation) EHRA Premium Access EHRA EUROPACE - CARDIOSTIM 2017

About the speaker

Photo
Doctor Olga Reynbakh

Montefiore Medical Center Albert Einstein College of Medicine, New York (United States of America)

8 More presentations in this session

Presentation thumbnail
Combined risk factors of an impaired fasting glucose and pre-hypertension are related to new onset atrial fibrillation in a healthy Asian population without underlying disease: A nationwide cohort stu
Doctor J. Park (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Patterns and predictors of anticoagulant prescribing for stroke prevention in patients with nonvalvular atrial fibrillation: results from the GARFIELD-AF registry
Professor J. Camm (London, GB)
Abstract
Presentation thumbnail
The long-term risk of atrial fibrillation and associated outcomes after carotid endarterectomy
Professor F. Leyva (Birmingham, GB)
Abstract Slides Video
Presentation thumbnail
Systematic screening for atrial fibrillation in 65-year-olds with risk factors for stroke. Data from the ACE 1950 Study
Doctor T. Berge (Baerum, NO)
Abstract Slides Video
Presentation thumbnail
Body fat distribution as risk factor of new-onset atrial fibrillation in The European Prospective Investigation Into Cancer and Nutrition in Norfolk Study
Ms J. Neefs (Amsterdam, NL)
Abstract Slides Video

Access the full session

Session thumbnail
Rapid Fire session 8 - Atrial fibrillation and stroke prevention

The Event

Event poster

EHRA EUROPACE - CARDIOSTIM 2017

21 June 2017 09:30 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources